Prices are updated after-hours

Nasdaq 2022 - 05 - 12

CyberOptics Corporation

CYBE | $54.0 -0.02%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (95.57% volume)
Earnings Calendar: 2022-10-26
Market Cap: $ 399,744,882
http://www.cyberoptics.com
Sec Filling | Patents | 173 employees

CyberOptics Corp. engages in designing, developing, and manufacturing of precision sensing technology solutions. Its products include metrology and three-dimensional scanning; surface mount technology (SMT); multi-reflection suppression (MRS); and semiconductor processes. The company was founded by Steven K. Case in 1984 and is headquartered in Minneapolis, MN.

semiconductor

add to watch list Paper trade email alert is off

CymaBay Therapeutics Inc.

CBAY | $32.48 0.03% 8.4M

Health Technology

(0.0% 1d) (0.0% 1m) (229.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-56.22% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 3,726,247,895
http://www.cymabay.com
Sec Filling | Patents | 60 employees

(US) CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

education liver liver disease

add to watch list Paper trade email alert is off

Diffusion Pharmaceuticals Inc.

DFFN 4 | $6.6 11.68% -34.32% 350K

Health Technology

(0.0% 1d) (0.0% 1m) (15.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (308.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 13,465,894
http://www.diffusionpharma.com
Sec Filling | Patents | 10 employees

(US) Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

treatment

add to watch list Paper trade email alert is off

Evelo Biosciences, Inc.

EVLO | $0.3165 -87.39% 710K

Health Technology

(0.0% 1d) (0.0% 1m) (-89.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.9% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 6,008,068
http://www.evelobio.com
Sec Filling | Patents | 98 employees

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

cancer msa treatment

add to watch list Paper trade email alert is off

Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K

Health Technology

(0.0% 1d) (0.0% 1m) (-77.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees

(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

cancer immunotherapy

add to watch list Paper trade email alert is off

Benefitfocus, Inc.

BNFT 4 | $10.5 0.1% 0

Technology Services

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (47.19% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 362,024,618
http://www.benefitfocus.com
Sec Filling | Patents | 1560 employees

(US) Benefitfocus, Inc. engages in the provision of cloud-based benefits management platform for consumers, employers, insurance carriers, and brokers. The company was founded by Mason R. Holland and Shawn A. Jenkins in June 2000 and is headquartered in Charleston, SC.

insurance

add to watch list Paper trade email alert is off

Brickell Biotech, Inc.

BBI | $2.12 16.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees

(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

dermatitis skin t-cell treatment ceiling

add to watch list Paper trade email alert is off

Casa Systems, Inc.

CASA | $0.055 -40.91% 65M

Electronic Technology

(0.0% 1d) (-82.6% 1m) (-95.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (17290.59% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,450,995
http://www.casa-systems.com
Sec Filling | Patents | 997 employees

(US) Casa Systems, Inc. engages in the provision and development of digital cable video and broadband services. Its products include cable, fixed, mobile, optical, and Wi-Fi networks; and casa access devices. The company was founded by Jerry Guo in 2003 and is headquartered in Andover, MA.

optical c-abl

add to watch list Paper trade email alert is off

Antares Pharma, Inc.

ATRS | $5.59 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (53.54% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.antarespharma.com
Sec Filling | Patents | 178 employees

(US) Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.

injection ycombinator

Drugs

Otrexup (methotrexate)
XYOSTED (testosterone enanthate)

add to watch list Paper trade email alert is off

Aptinyx Inc.

APTX | $0.061 21.31% 7.8M

Health Services

(0.0% 1d) (0.0% 1m) (-49.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (429.23% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 4,130,659
http://www.aptinyx.com
Sec Filling | Patents | 43 employees

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

nervous system nyx-458

add to watch list Paper trade email alert is off

Aravive, Inc.

ARAV | $0.0401 4.74% 4M

Health Technology

(0.0% 1d) (0.0% 1m) (-97.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees

(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

cancer t-cell ovarian cancer treatment ceiling

add to watch list Paper trade email alert is off

Checkmate Pharmaceuticals, Inc.

CMPI | $10.5 0.0%

Health Technology

(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

cancer

add to watch list Paper trade email alert is off

Athersys, Inc.

ATHX | $0.1018 -40.86% 95M

Health Technology

(0.0% 1d) (0.0% 1m) (-87.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
Sec Filling | Patents | 83 employees

(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

cardiovascular stem cell urea t-cell neurological ceiling

add to watch list Paper trade email alert is off

BCLS Acquisition Corp.

BLSA | $10.035 0.0%

Finance

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (28.89% volume)
Earnings Calendar:
Market Cap: $ 149,145,188
https://bclsacquisitioncorp.com
Sec Filling | Patents | n/a employees

BCLS Acquisition Corp. is a blank check company, which engages in seeking a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on August 26, 2020 and is headquartered in Boston, MA.

acquisitions blank check

add to watch list Paper trade email alert is off

Bed Bath & Beyond Inc.

BBBY | $0.0751 -27.09% -47.14% 190M

Retail Trade

(0.0% 1d) (0.0% 1m) (-62.3% 1y) (0.0% 2d) (0.0% 3d) (-27.1% 7d) (55.07% volume)
Earnings Calendar: 2023-05-11
Market Cap: $ 41,961,072
http://www.bedbathandbeyond.com
Sec Filling | Patents | 55000 employees

(US) Bed Bath & Beyond, Inc. engages in the operation of retail stores and retails domestics merchandise and home furnishings. Its products include domestic merchandise and home furnishings such as bed linens and related items, bath items, kitchen textiles kitchen and tabletop items, fine tabletop, basic house wares, general home furnishings, and consumables. The company was founded by Warren Eisenberg and Leonard Feinstein in 1971 and is headquartered in Union, NJ.

housing

Drugs

menthol cough drops (Menthol)

add to watch list Paper trade email alert is off

Concert Pharmaceuticals, Inc.

CNCE | $8.37 0.36% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees

(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

autoimmunity nervous system molecule drugs

add to watch list Paper trade email alert is off

Akouos, Inc.

AKUS | $13.29 1.07% 3.46%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap:
http://www.akouos.com
Sec Filling | Patents | 54 employees

Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.

gene therapies t-cell genetic hearing loss ceiling

add to watch list Paper trade email alert is off

Fennec Pharmaceuticals Inc.

FENC M | $10.5 -3.05% -3.14% 100K

Health Technology

(0.0% 1d) (-1.5% 1m) (36.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-29.88% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 284,598,668
http://www.fennecpharma.com
Sec Filling | Patents | 4 employees

(US) Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

cancer msa

add to watch list Paper trade email alert is off

Global Blood Therapeutics, Inc.

GBT | $68.49 0.02% -0.02%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees

(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

t-cell ceiling

Drugs

OXBRYTA (Voxelotor)

add to watch list Paper trade email alert is off

Harbor Custom Development, Inc.

HCDI | $0.199 -24.47% 1.2M

Finance

(0.0% 1d) (0.0% 1m) (-94.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.35% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 463,535
http://harborcustomhomes.com
Sec Filling | Patents | 40 employees

(US) Harbor Custom Development, Inc. is an emerging growth company, which engages in the construction, sale, and management of residential properties. Its portfolio includes single-family lots, multi-family properties, and home communities. The company was founded by Sterling Griffin in February 2014 and is headquartered in Gig Harbor, WA.

construction

add to watch list Paper trade email alert is off